Novo Nordisk A/S (NOVO-B.CO)

862,70 -8,60 (-0,99%) Börsenschluss: 04:59PM CEST

Novo Nordisk A/S

Novo Alle 1
Bagsvaerd 2880
Denmark
45 44 44 88 88
https://www.novonordisk.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 63.370

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Lars Fruergaard Jorgensen	President, CEO & Member of Management Board	32,3M	N/A	1966
Mr. Karsten Munk Knudsen	Executive VP, CFO & Member of the Management Board	12,8M	N/A	1971
Mr. Henrik Ehlers Wulff	Executive VP of Product Supply, Quality & IT and Member of the Management Board	12,9M	N/A	1970
Ms. Camilla Sylvest	Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board	12,6M	N/A	1972
Dr. Martin Holst Lange	Executive VP of Development & Member of the Management Board	12,2M	N/A	1970
Dr. Marcus Schindler Ph.D.	EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board	12,2M	N/A	1966
Mr. Maziar Mike Doustdar	Executive VP of International Operations & Member of the Management Board	N/A	N/A	1970
Mr. Douglas J. Langa	Executive VP of North America Operations & Member of Management Board	N/A	N/A	1966
Mr. Ludovic Helfgott	Executive VP, Head of Rare Disease & Member of Management Board	N/A	N/A	1974
Ms. Tania Sabroe	Executive VP of Global People & Organisation and Member of Management Board	N/A	N/A	1977

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in DKK.

Beschreibung

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Corporate Governance

Novo Nordisk A/Ss ISS Governance QualityScore, Stand 1. April 2024, lautet 1. Die grundlegenden Scores sind Audit: 2, Vorstand: 2, Shareholderrechte: 9, Kompensation: 1.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.